Why Zealand Pharma stock moves
Zealand Pharma moved little without a company-news explanation.
Written after the close on ·
Earnings report
Next report: November 12. On its last 15 report days Zealand Pharma usually moved about 4.3%. On a normal day it moves 1.4%.
August 13, 2026: +3.65%August 7, 2026: +0.82%May 7, 2026: +9.45%February 19, 2026: −3.43%
Why today
16,307 news analyzed todayZealand Pharma moved little without a company-news explanation.
Over the last five trading days it rose slightly, in line with OMX Copenhagen 25, which rose clearly.
The shares sit well below their highest close of the past year and above the lowest.
Watch the third quarter results and conference call on Thursday 12 November 2026.
Today's move of −0.21% was 0.2 times a normal day's 1.4%. OMX Copenhagen 25 moved −0.23% on the same day.
Zealand Pharma −0.21%OMX Copenhagen 25 −0.23%In step with the market
What analysts expect, and how often they have been right
Analysts’ estimates for Zealand Pharma.
Zealand Pharma earned more than expected in 4 out of 8 reports.
Not in the chart because no estimate and result are available: 1 of the 9 reports in this period, the latest on August 6, 2026.
For comparison, about 46% of reports from Nordic companies beat the estimate in the last three years.
The share moved in the same direction as the earnings surprise in 4 out of 8 reports with a measured move, against about 63% of reports from Nordic companies.
Ratings
Price targets
Latest price 232.90 DKK
Earnings against expectations, and the share’s reaction
Expected EPSAbove estimateBelow estimateAs expectedDKK
Next reported quarter: expected earnings per share of -10.91 DKK (November 12). For the current fiscal year, expected earnings per share changed from 22.48 DKK three months ago to 27.55 DKK now. 2026 estimate: 27.55 DKK. 2027 estimate: 7.15 DKK.
Has the share price followed the business?
Price and earnings moved in the same direction: 1 out of 3 years. Across Nordic companies, that happens in about 60% of years. In 2025, the price changed −35% and earnings per share went from -16.24 DKK to 90.22 DKK.
Revenue, profit and market cap
RevenueProfitMarket capHatched bars: analysts’ estimates.bn DKK
Assets, liabilities and market cap
AssetsLiabilitiesMarket capbn DKK
Price and earnings moved in the same direction: 1 out of 3 years.Market cap (Now): 15.4 bn DKKRevenue 2025: 9.2 bn DKK
What the key figures say about Zealand Pharma
The figures connect what Zealand Pharma earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: -26.02 DKK–90.22 DKK. Peers: Intellia Therapeutics -$3.35, Rapport Therapeutics -$3.17, AbCellera Biologics -$0.54. 2026 estimate: 27.55 DKK (19.11 DKK–32.80 DKK). 2027 estimate: 7.15 DKK (-36.60 DKK–41.38 DKK).
What the company sold during the year.
2022–2025: 62.7 m DKK–9.2 bn DKK. Peers: Intellia Therapeutics $59.5M, Rapport Therapeutics $20.0M, AbCellera Biologics $66.2M. 2026 estimate: 4.8 bn DKK (4.5 bn DKK–5.3 bn DKK). 2027 estimate: 4.2 bn DKK (888 m DKK–6.8 bn DKK).
The percentage of revenue left after the costs of running the business.
2022–2025: −2024.3%–77.2%. Peers: Intellia Therapeutics −711.7%, Rapport Therapeutics −838.1%, AbCellera Biologics −318.7%.
Profit as a percentage of shareholders’ money in the company.
2022–2025: −147.3%–43.5%. Peers: Intellia Therapeutics −55.4%, Rapport Therapeutics −33.3%, AbCellera Biologics −17.3%.
The price investors pay for each unit of annual earnings per share. Not shown for a loss.
2022–2025: 5.2–5.2. 2026 estimate: 8.5. 2027 estimate: 32.6.
What investors pay for each unit the company sells.
2022–2025: 3.57–806.34. Peers: Intellia Therapeutics 26.77, Rapport Therapeutics 72.44, AbCellera Biologics 58.18. 2026 estimate: 3.23. 2027 estimate: 3.65.
Net debt divided by operating earnings before depreciation and amortisation.
2022–2025: -2.08–-2.08.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2022–2025: 2.22–13.68. Peers: Intellia Therapeutics 1.97, Rapport Therapeutics 3.00, AbCellera Biologics 4.06.
Market cap plus net debt, divided by operating earnings. This includes debt.
2022–2025: 2.6–2.6.
Cash left after investments, divided by the number of shares.
2022–2025: -18.53 DKK–91.53 DKK. Peers: Intellia Therapeutics -$2.48, Rapport Therapeutics -$2.04, AbCellera Biologics -$0.37.
The percentage of assets financed by shareholders’ equity.
2022–2025: 53.0%–93.0%.
What to watch next, and why
The earnings report shows how Zealand Pharma's revenue and profit have changed.
- Earnings report
The earnings report shows how Zealand Pharma's revenue and profit have changed.
Add to calendar
Earnings report
Next report: · Add to calendar · Google Calendar
On its last 15 report days Zealand Pharma usually moved about 4.3%. On a normal day it moves 1.4%.
+3.65% +0.82% +9.45% −3.43%
10,000 DKK in Zealand Pharma bought on November 7, 2016 is worth 26,100 DKK today, with dividends reinvested.
The same amount in OMX Copenhagen with dividends would have become 25,800 DKK.
What would 10,000 DKK in Zealand Pharma be worth today? →
What would 10,000 DKK in Zealand Pharma be worth today?
26,100 DKK
with dividends reinvested, bought on November 7, 2016. The same amount in OMX Copenhagen with dividends would have become 25,800 DKK.
At worst it was worth 7,950 DKK (May 16, 2022).
The five biggest days of the journey
· +37.9% · the whole market rose 0.4% the same day
· −36.4% · the whole market fell 1.6% the same day
· +35.7% · the whole market rose 0.3% the same day
· +28.5% · the whole market rose 1.4% the same day
· −22.7% · the whole market fell 0.9% the same day
Earlier days
+1.20% market +1.82% Zealand Pharma rose slightly without a company-news explanation. Read →
Zealand Pharma rose slightly without a company-news explanation.
Over the same days, OMX Copenhagen 25 rose sharply, so the stock moved less than the market.
Over the last five trading days it rose slightly, in line with the market.
Earlier news was analyst ratings and a Phase 1 safety result, which do not explain this session.
The next earnings report is on Thursday 12 November 2026, when the company reports its results.
+1.17% market +0.22% Zealand Pharma rose slightly without a company-news explanation. Read →
Zealand Pharma rose slightly without a company-news explanation.
Over the same day OMX Copenhagen 25 rose slightly too, so the stock moved a bit more than the market.
Over the last five trading days the shares rose slightly while the market rose sharply, so the stock moved in line with it over that stretch.
The move was an ordinary one for Zealand Pharma, within its usual daily range.
Recent news was analyst ratings and early safety results, which are older background rather than the cause of this session.
+0.91% market +0.07% Zealand Pharma rose slightly without company news. Read →
Zealand Pharma rose slightly without company news.
Over the same day, OMX Copenhagen 25 was roughly flat, so the move was not market-driven.
Over the last five trading days, the shares rose slightly, in line with a sharply rising market.
The move was an ordinary one for the stock, and trading was well below its usual level.
Earlier Phase 1 safety results, the early-stage human safety trial, were published before the session and are dated background.
+1.68% market +2.33% Zealand Pharma rose, in line with the market. Read →
Zealand Pharma rose, in line with the market.
Over the last five trading days the shares were roughly unchanged, while OMX Copenhagen 25 rose sharply, so the stock lagged.
The move was an ordinary one for Zealand Pharma, within its usual daily range.
No company news from the last session explains the move; the Phase 1 results for ZP9830, a Kv1.3 ion channel blocker (a drug target that calms immune cells), came out the week before.
The next earnings report, a company's scheduled results update, is due Thursday 12 November 2026.
+1.21% market +0.57% Zealand Pharma rose slightly without a company-news explanation. Read →
Zealand Pharma rose slightly without a company-news explanation.
Over the last five trading days, Zealand Pharma fell slightly while OMX Copenhagen 25 rose sharply.
The last session's move was an ordinary one for Zealand Pharma, and it moved a little more than the market.
Earlier, Zealand Pharma reported positive early-stage trial results for its ZP9830 drug candidate, which likely weighed on sentiment less than hoped.
Next, Zealand Pharma reports earnings on Thursday 12 November 2026.
−2.33% market −0.63% Zealand Pharma fell clearly, more than the market. Read →
Zealand Pharma fell clearly, more than the market.
The market also fell clearly that day, so the move was largely in line with it.
No company news from the last session explains the drop.
Over the last five trading days the shares were roughly unchanged, while the market rose slightly.
Trading volume was well below normal, and the shares sit near their one-year low.
−0.13% market +0.86% Zealand Pharma was roughly unchanged over the last five trading days. Read →
Zealand Pharma was roughly unchanged over the last five trading days.
It moved less than the market.
OMX Copenhagen 25 rose slightly over the same days.
The main news was positive Phase 1 results on Monday and Tuesday for ZP9830, a drug that blocks an immune channel called Kv1.3.
+3.61% market −0.08% Zealand Pharma rose clearly on positive trial news for ZP9830. Read →
Zealand Pharma rose clearly on positive trial news for ZP9830.
Over the same days the wider Copenhagen market was roughly flat, so the move was company-specific.
The company reported positive Phase 1 results for its ZP9830 drug, showing multiple doses were safe and well tolerated.
Phase 1 is an early trial in healthy volunteers that checks safety, and a clean result like this usually lifts a biotech's shares.
Over the last five trading days the stock was roughly unchanged.
Learn more · Why do stocks move on earnings day? · Why do stocks go up and down?